Viome has announced that it will be partnering with Henry Schein to provide better access to Viome’s Oral Health Pro With CancerDetect.* Viome’s laboratory-developed test* helps detect early biomarkers of oral and throat cancers, enhancing practitioners’ ability to effectively harness the power of preventive care and improve patient outcomes.
Henry Schein will be the first stop for clinicians who want to order Oral Health Pro With CancerDetect, for their patients, and will provide access to the test. After the healthcare professionals have captured a saliva sample, a sample will be sent to Viome’s high complexity CLIA lab for testing. Results are posted on a secure portal for the clinician and patient in 1-2 weeks, so that health professionals and patients can review the results together.
Viome is a longevity and preventive healthcare company committed to bridging the gap between scientific breakthroughs and their practical implementation as health solutions. The company provides home-based tests which offer individuals personalised nutritional guidance and innovative microbiome health products to enhance lifespan and health.
Dr Ed Zuckerberg DDS FAGD, chief dental officer at Viome, highlights the transformative impact of Viome’s test and Henry Schein’s unique ability to help generate greater access across healthcare.
“The traditional approach to oral care has been predominantly reliant on visual and tactile examinations. With new research and technology, we can now better understand the risks for oral health diseases and better detect the onset of oral and throat cancer. Oral Health Pro With CancerDetect can help change oral healthcare for both patients and medical professionals who never had access to this type of test. Our collaboration with Henry Schein extends the power of preventive care and it enables dentists and medical professionals to be more effective in their treatments, fundamentally changing the game,” said Dr Zuckerberg.
According to Nutrients, an international, peer-reviewed, open access journal of human nutrition, there are over 400,000 new cases of oral cancer reported annually in the US alone, reflecting the need for reliable oral and throat cancer detection.
“At Henry Schein, we are pleased to deliver the first crucial step in Viome’s process for detecting biomarkers associated with oral or throat cancer, marking a significant advancement for Henry Schein’s product offerings and dentistry at large in helping to prevent cancer,” said Dr Bruce Lieberthal, vice-president and chief innovation officer at Henry Schein.
Lieberthal added: “Understanding the importance of early detection and intervention, we are pleased to be able to work with Viome to enhance patient outcomes and usher in a new era for dental and medical professionals. Our vision is to help lead a transformation where oral care prioritises prevention, focusing on the patient’s health and well-being in and outside dental and medical offices. This is a pivotal step in redefining the current standard of care, where early action and prevention lead to a healthier society.”
* Viome’s Oral Health Pro With CancerDetect is a laboratory developed test that was validated, pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA), and as such it has not been reviewed by FDA. As with any test, there may be false positives or false negatives.
Related: Henry Schein One partners with 42 North Dental to drive cloud technology and AI diagnostics
